Comparative Pharmacology
Head-to-head clinical analysis: HMS versus VEXOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HMS versus VEXOL.
HMS vs VEXOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HMS is a synthetic androgen and anabolic steroid that acts as an agonist at androgen receptors, promoting protein synthesis and muscle growth.
Selective glucocorticoid receptor agonist; binds to cytoplasmic receptors leading to inhibition of phospholipase A2, suppression of inflammatory mediators, and vasoconstriction.
No established standard dosing for HMS as it is not a recognized therapeutic agent. Please verify the drug name.
1-2 drops of 1% ophthalmic suspension in the conjunctival sac of the affected eye(s) four times daily. In severe conditions, may increase frequency to every 2 hours during initial 24-48 hours.
None Documented
None Documented
3–5 hours; prolonged in renal impairment (up to 15 hours), requiring dose adjustment
Terminal elimination half-life is approximately 2.3 hours in adults. This short half-life supports twice-daily dosing for maintenance of therapeutic effect.
Renal (70% unchanged), biliary/fecal (20% as metabolites), 10% other
Primarily hepatic metabolism with biliary excretion of metabolites. Renal excretion accounts for <2% of unchanged drug. Fecal elimination of metabolites is the major route (>90%).
Category C
Category C
Corticosteroid (Ophthalmic)
Corticosteroid (Ophthalmic)